Browse Government Accountability Office (GAO) reports by subject "Prescription drugs"- LegiStorm

Weekly Updates

LegiStorm is constantly adding new information on the people, places and reports in our database. In the past week, LegiStorm added:

376 new people
171 new organizations
408 new photos
1234 job history records for people in our database
653 education records for people in our database
1467 contact addresses, emails and URLs (LinkedIn, Facebook, etc.)
3 new people through the revolving door
109 new policy reports
43 new trips to our privately funded travel database
629 new personal financial disclosures
15148 new press releases
11 new town halls
25 new hearings

Caught Our Eye Rss

Some legislators prioritize talk, not action

by Heavyn Lester on 09/23/2024
Former state sen. joins conservative immigration group

by Heavyn Lester on 09/17/2024
Some representatives are burning through their budgets

by Heavyn Lester on 09/16/2024
Burlison hires foul-mouthed comms specialist

by Andy Gottlieb on 09/13/2024
Lobbyist returns to Senate as chief of staff

by Heavyn Lester on 09/12/2024

» More from Caught Our Eye

Follow @LegiStorm

LegiStorm adds House Q2 salaries and expenses

2024-09-05
Latest Senate salary and expense records published

2024-06-10
LegiStorm adds House Q1 salaries and expenses

2024-06-05
LegiStorm adds Q4 salary analytics and turnover data

2024-03-14

» More from our DevBlog

Lobbyists exploit massive loophole to wine and dine lawmakers, aides at fancy getaways

by Politico on 09/22/2024
Vulnerable Dem senator who touts record 'fighting' lobbyists has long history of hiring them

by Fox News on 09/18/2024
Kamala Harris ran her office like a prosecutor. Not everyone liked that.

by The Washingon Post on 09/09/2024
Letter: Van Ostern’s recent flyer

by Concord Monitor on 08/29/2024

GAO Reports by subject "Prescription drugs"

Full-text search of 51,869 reports from the Government Accountability Office

Full-text search

Report type

Period From To

Title

Report or Bill No.

Reset

Search Results:

Date	Report No.	Title
Date Dec. 1, 2011	Report No. GAO-12-270T	Title Foster Children: HHS Guidance Could Help States Improve Oversight of Psychotropic Prescriptions GAO For Release on Delivery Expected at 10:30 a.m. EST Thursday, December 1, 2011 United States Government Accountability Office Testimony Before the Subcommittee on Federal Financial Management, Government Information, Federal Services, and International Security, Committee on Homeland Security and Governmental Affairs, U.S. Senate FOSTER CHILDREN HHS Guidance Could Help States Improve Oversight ...
Date Oct. 4, 2011	Report No. GAO-12-104T	Title Medicare Part D: Instances of Questionable Access to Prescription Drugs United States Government Accountability Office GAO For Release on Delivery Expected at 10:30 a.m. EDT Tuesday, October 4, 2011 Testimony Before the Subcommittee on Federal Financial Management, Government Information, Federal Services, and International Security, Committee on Homeland Security and Governmental Affairs, U.S. Senate MEDICARE PART D Instances of Questionable Access to Prescription Dr...
Date Sept. 6, 2011	Report No. GAO-11-699	Title Medicare Part D: Instances of Questionable Access to Prescription Drugs United States Government Accountability Office GAO September 2011 Report to Congressional Requesters MEDICARE PART D Instances of Questionable Access to Prescription Drugs GAO-11-699 September 2011 MEDICARE PART D Instances of Questionable Access to Prescription Drugs Highlights of GAO-11-699, a report to congressional requesters Why GAO Did This Study In 2009, GAO reported on doctor shopping in M...
Date Aug. 26, 2011	Report No. GAO-11-744	Title Prescription Drug Control: DEA Has Enhanced Efforts to Combat Diversion, but Could Better Assess and Report Program Results United States Government Accountability Office GAO August 2011 Report to Congressional Requesters PRESCRIPTION DRUG CONTROL DEA Has Enhanced Efforts to Combat Diversion, but Could Better Assess and Report Program Results GAO-11-744 August 2011 PRESCRIPTION DRUG CONTROL DEA Has Enhanced Efforts to Combat Diversion, but Could Better Assess and Report Program Results Highlights of GAO-11-744, a repor...
Date Aug. 4, 2011	Report No. GAO-11-735R	Title World Trade Center Health Program: Potential Effects of Implementation Options United States Government Accountability Office Washington, DC 20548 August 4, 2011 The Honorable Tom Harkin Chairman The Honorable Michael B. Enzi Ranking Member Committee on Health, Education, Labor, and Pensions United States Senate The Honorable Fred Upton Chairman The Honorable Henry A. Waxman Ranking Member Committee on Energy and Commerce United States House of Representatives Subject: World...
Date June 22, 2011	Report No. GAO-11-546R	Title Medicare Part D: Changes in Utilization Similar for Randomly Reassigned and Other Low-Income Subsidy Beneficiaries United States Government Accountability Office Washington, DC 20548 June 22, 2011 The Honorable Henry Waxman Ranking Member Committee on Energy and Commerce House of Representatives The Honorable Frank Pallone Ranking Member Subcommittee on Health Committee on Energy and Commerce House of Representatives The Honorable John D. Dingell House of Representatives Subject: Medicare Part D: Changes in Ut...
Date June 1, 2011	Report No. GAO-11-406	Title Antibiotic Resistance: Data Gaps Will Remain Despite HHS Taking Steps to Improve Monitoring United States Government Accountability Office GAO June 2011 Report to the Committee on Agriculture, House of Representatives ANTIBIOTIC RESISTANCE Data Gaps Will Remain Despite HHS Taking Steps to Improve Monitoring GAO-11-406 June 2011 ANTIBIOTIC RESISTANCE Accountability • Integrity • Reliability Data Gaps Will Remain Despite HHS Taking Steps to Improve Monitoring Highlights of GAO-11-406, ...
Date March 23, 2011	Report No. GAO-11-365	Title End-Stage Renal Disease: CMS Should Assess Adequacy of Payment When Certain Oral Drugs Are Included and Ensure Availability of Quality Monitoring Data United States Government Accountability Office GAO March 2011 Report to Congressional Committees END-STAGE RENAL DISEASE CMS Should Assess Adequacy of Payment When Certain Oral Drugs Are Included and Ensure Availability of Quality Monitoring Data GAO-11-365 March 2011 END-STAGE RENAL DISEASE Accountability • Integrity • Reliability CMS Should Assess Adequacy of Payment When Certain Oral Drugs ...
Date Feb. 18, 2011	Report No. GAO-11-269R	Title Medicare Part D: CMS Conducted Fraud and Abuse Compliance Plan Audits, but All Audit Findings Are Not Yet Available United States Government Accountability Office Washington, DC 20548 February 18, 2011 The Honorable Thomas R. Carper Chairman Subcommittee on Federal Financial Management, Government Information, Federal Services, and International Security Committee on Homeland Security and Governmental Affairs United States Senate The Honorable John McCain United States Senate Subject: Medicare Part D: CMS Condu...
Date Feb. 10, 2011	Report No. GAO-11-306R	Title Prescription Drugs: Trends in Usual and Customary Prices for Commonly Used Drugs United States Government Accountability Office Washington, DC 20548 February 10, 2011 Congressional Requesters Subject: Prescription Drugs: Trends in Usual and Customary Prices for Commonly Used Drugs Prescription drug spending in 2009 totaled approximately $250 billion, of which $78 billion— or about 31 percent—was spent by the federal government. 1 Prescription drug spending by the federal g...
Date Dec. 15, 2010	Report No. GAO-11-141R	Title Medicaid Outpatient Prescription Drugs: Estimated Changes to Federal Upper Limits Using the Formula under the Patient Protection and Affordable Care Act United States Government Accountability Office Washington, DC 20548 December 15, 2010 The Honorable Henry A. Waxman Chairman Committee on Energy and Commerce House of Representatives Subject: Medicaid Outpatient Prescription Drugs: Estimated Changes to Federal Upper Limits Using the Formula under the Patient Protection and Affordable Care Act Dear Mr. Chairman: Spending on prescription drugs in Me...
Date Oct. 29, 2010	Report No. GAO-11-95	Title Food and Drug Administration: Response to Heparin Contamination Helped Protect Public Health; Controls That Were Needed for Working With External Entities Were Recently Added United States Government Accountability Office GAO October 2010 Report to the Ranking Member, Committee on Energy and Commerce, House of Representatives FOOD AND DRUG ADMINISTRATION Response to Heparin Contamination Helped Protect Public Health; Controls That Were Needed for Working With External Entities Were Recently Added GAO-11-95 October 2010 FOOD AND DRUG ADMINISTRATION Accountability • In...
Date March 17, 2010	Report No. GAO-10-529T	Title Medicare Part D: Spending, Beneficiary Out-of-Pocket Costs, and Efforts to Obtain Price Concessions for Certain High-Cost Drugs United States Government Accountability Office GAO For Release on Delivery Expected at 2:30 p.m. EDT Wednesday, March 17, 2010 Testimony Before the Special Committee on Aging, U.S. Senate MEDICARE PART D Spending, Beneficiary Outof-Pocket Costs, and Efforts to Obtain Price Concessions for Certain High-Cost Drugs Statement of John E. Dicken Director, Health Care GAO-10-529T March 17, 2010 MEDICARE ...
Date March 3, 2010	Report No. GAO-10-481T	Title Medicare Part D: CMS Oversight of Part D Sponsors' Fraud and Abuse Programs Has Been Limited, but CMS Plans Oversight Expansion United States Government Accountability Office GAO For Release on Delivery Expected at 2:30 p.m. EST Wednesday, March 3, 2010 Testimony Before the Subcommittee on Federal Financial Management, Government Information, Federal Services, and International Security, Homeland Security and Governmental Affairs Committee, U.S. Senate MEDICARE PART D CMS Oversight of Part D Sponsors’ Fraud and Abuse Pro...
Date Jan. 29, 2010	Report No. GAO-10-242	Title Medicare Part D: Spending, Beneficiary Cost Sharing, and Cost-Containment Efforts for High-Cost Drugs Eligible for a Specialty Tier United States Government Accountability Office GAO January 2010 Report to the Chairman, Subcommittee on Health, Committee on Ways and Means, House of Representatives MEDICARE PART D Spending, Beneficiary Cost Sharing, and Cost-Containment Efforts for High-Cost Drugs Eligible for a Specialty Tier GAO-10-242 January 2010 MEDICARE PART D Highlights Highlights of GAO-10-242, a report to the Chairman, ...
Date Dec. 28, 2009	Report No. GAO-10-185	Title Medicare Managed Care: Observations about Medicare Cost Plans United States Government Accountability Office GAO December 2009 Report to Congressional Committees MEDICARE MANAGED CARE Observations about Medicare Cost Plans GAO-10-185 December 2009 MEDICARE MANAGED CARE Highlights Highlights of GAO-10-185, a report to congressional committees Accountability Integrity Reliability Observations about Medicare Cost Plans Why GAO Did This Study Medicare cost plans...
Date Dec. 22, 2009	Report No. GAO-10-201	Title Brand-Name Prescription Drug Pricing: Lack of Therapeutically Equivalent Drugs and Limited Competition May Contribute to Extraordinary Price Increases United States Government Accountability Office GAO December 2009 Report to Congressional Requesters BRAND-NAME PRESCRIPTION DRUG PRICING Lack of Therapeutically Equivalent Drugs and Limited Competition May Contribute to Extraordinary Price Increases GAO-10-201 December 2009 BRAND-NAME PRESCRIPTION DRUG PRICING Highlights Highlights of GAO-10-201, a report to congressional requesters Accountability...
Date Nov. 30, 2009	Report No. GAO-10-118R	Title Medicaid Outpatient Prescription Drugs: Second Quarter 2008 Federal Upper Limits for Reimbursement Compared with Average Retail Pharmacy Acquisition Costs United States Government Accountability Office Washington, DC 20548 November 30, 2009 The Honorable Charles E. Grassley Ranking Member Committee on Finance United States Senate Subject: Medicaid Outpatient Prescription Drugs: Second Quarter 2008 Federal Upper Limits for Reimbursement Compared with Average Retail Pharmacy Acquisition Costs Dear Senator Grassley: Medicaid—the joint federal-state p...
Date Sept. 30, 2009	Report No. GAO-09-1004T	Title Medicaid: Fraud and Abuse Related to Controlled Substances Identified in Selected States United States Government Accountability Office GAO For Release on Delivery Expected at 3:00 p.m. EDT Wednesday, September 30, 2009 Testimony before the Subcommittee on Federal Financial Management, Government Information, Federal Services, and International Security, Committee on Homeland Security and Governmental Affairs, U.S. Senate MEDICAID Fraud and Abuse Related to Controlled Substances Ident...
Date Sept. 9, 2009	Report No. GAO-09-957	Title Medicaid: Fraud and Abuse Related to Controlled Substances Identified in Selected States United States Government Accountability Office GAO September 2009 Report to Congressional Requesters MEDICAID Fraud and Abuse Related to Controlled Substances Identified in Selected States GAO-09-957 September 2009 MEDICAID Highlights Highlights of GAO-09-957, a report to congressional requesters Accountability Integrity Reliability Fraud and Abuse Related to Controlled Substances Identified in Se...
Date July 30, 2009	Report No. GAO-09-752R	Title Centers for Medicare & Medicaid Services: CMS Should Develop an Agencywide Policy for Translating Medicare Documents into Languages Other Than English United States Government Accountability Office Washington, DC 20548 July 30, 2009 The Honorable Nydia M. Velázquez Chairwoman Committee on Small Business House of Representatives Subject: Centers for Medicare & Medicaid Services: CMS Should Develop an Agencywide Policy for Translating Medicare Documents into Languages Other Than English Dear Chairwoman Velázquez: The Department of Health and Hum...
Date June 24, 2009	Report No. GAO-09-819T	Title Prescription Drugs: Overview of Approaches to Control Prescription Drug Spending in Federal Programs United States Government Accountability Office GAO For Release on Delivery Expected at 2:00 p.m. EDT Wednesday, June 24, 2009 Testimony Before the Subcommittee on Federal Workforce, Postal Service, and the District of Columbia, Committee on Oversight and Government Reform, House of Representatives PRESCRIPTION DRUGS Overview of Approaches to Control Prescription Drug Spending in Federal Programs S...
Date March 26, 2009	Report No. GAO-09-341	Title Methadone-Associated Overdose Deaths: Factors Contributing to Increased Deaths and Efforts to Prevent Them United States Government Accountability Office GAO March 2009 Report to Congressional Requesters METHADONEASSOCIATED OVERDOSE DEATHS Factors Contributing to Increased Deaths and Efforts to Prevent Them GAO-09-341 March 2009 Highlights Highlights of GAO-09-341, a report to congressional requesters Accountability Integrity Reliability METHADONE-ASSOCIATED OVERDOSE DEATHS Factors Contributing to Incr...
Date Feb. 20, 2009	Report No. GAO-09-245	Title Nonprescription Drugs: Considerations Regarding a Behind-the-Counter Drug Class United States Government Accountability Office GAO February 2009 Report to Congressional Requesters NONPRESCRIPTION DRUGS Considerations Regarding a Behind-the-Counter Drug Class GAO-09-245 February 2009 NONPRESCRIPTION DRUGS Highlights Highlights of GAO-09-245, a report to congressional requesters Accountability Integrity Reliability Considerations Regarding a Behind-the-Counter Drug Class Why GA...
Date Dec. 12, 2008	Report No. GAO-09-4	Title Medicare Part D: Opportunities Exist for Improving Information Sent to Enrollees and Scheduling the Annual Election Period United States Government Accountability Office GAO December 2008 Report to the Chairman, Committee on Energy and Commerce, House of Representatives MEDICARE PART D Opportunities Exist for Improving Information Sent to Enrollees and Scheduling the Annual Election Period GAO-09-4 December 2008 MEDICARE PART D Highlights Highlights of GAO-09-4, a report to the Chairman, Committee on Energy and Commer...
Date Sept. 30, 2008	Report No. GAO-08-1074R	Title Medicare Part D Prescription Drug Coverage: Federal Oversight of Reported Price Concessions Data United States Government Accountability Office Washington, DC 20548 September 30, 2008 The Honorable Henry A. Waxman Chairman Committee on Oversight and Government Reform House of Representatives Subject: Medicare Part D Prescription Drug Coverage: Federal Oversight of Reported Price Concessions Data Dear Mr. Chairman: To help Medicare beneficiaries manage the rising cost of prescription drugs, Co...
Date Sept. 5, 2008	Report No. GAO-08-824	Title Medicare Part D Low-Income Subsidy: Assets and Income Are Both Important in Subsidy Denials, and Access to State and Manufacturer Drug Programs Is Uneven United States Government Accountability Office GAO September 2008 Report to Congressional Committees MEDICARE PART D LOW-INCOME SUBSIDY Assets and Income Are Both Important in Subsidy Denials, and Access to State and Manufacturer Drug Programs Is Uneven GAO-08-824 September 2008 MEDICARE PART D LOW-INCOME SUBSIDY Highlights Highlights of GAO-08-824, a report to congressional committees Accountabil...
Date Aug. 7, 2008	Report No. GAO-08-751	Title Food and Drug Administration: Approval and Oversight of the Drug Mifeprex United States Government Accountability Office GAO August 2008 Report to Congressional Requesters FOOD AND DRUG ADMINISTRATION Approval and Oversight of the Drug Mifeprex GAO-08-751 August 2008 FOOD AND DRUG ADMINISTRATION Highlights Highlights of GAO-08-751, a report to congressional requesters Accountability Integrity Reliability Approval and Oversight of the Drug Mifeprex Why GAO Did This Study...
Date July 28, 2008	Report No. GAO-08-835	Title Prescription Drugs: FDA's Oversight of the Promotion of Drugs for Off-Label Uses United States Government Accountability Office GAO July 2008 Report to the Ranking Member, Committee on Finance, U.S. Senate PRESCRIPTION DRUGS FDA’s Oversight of the Promotion of Drugs for Off-Label Uses GAO-08-835 July 2008 PRESCRIPTION DRUGS Highlights Highlights of GAO-08-835, a report to the Ranking Member, Committee on Finance, U.S. Senate Accountability Integrity Reliability FDA’s Overs...
Date July 21, 2008	Report No. GAO-08-760	Title Medicare Part D: Some Plan Sponsors Have Not Completely Implemented Fraud and Abuse Programs, and CMS Oversight Has Been Limited United States Government Accountability Office GAO July 2008 Report to the Ranking Member, Committee on Finance, U.S. Senate MEDICARE PART D Some Plan Sponsors Have Not Completely Implemented Fraud and Abuse Programs, and CMS Oversight Has Been Limited GAO-08-760 July 2008 MEDICARE PART D Highlights Highlights of GAO-08-760, a report to the Ranking Member, Committee on Finance, U.S. Senate Account...
Date May 22, 2008	Report No. GAO-08-812T	Title Medicare Part D Low-Income Subsidy: SSA Continues to Approve Applicants, but Millions of Individuals Have Not Yet Applied United States Government Accountability Office GAO For Release on Delivery Expected at 10:30 a.m. EDT Thursday, May 22, 2008 Testimony Before the Special Committee on Aging, U.S. Senate MEDICARE PART D LOWINCOME SUBSIDY SSA Continues to Approve Applicants, but Millions of Individuals Have Not Yet Applied Statement of Barbara D. Bovbjerg, Director Education, Workforce, and Income Security Issues GA...
Date May 8, 2008	Report No. GAO-08-758T	Title Prescription Drugs: Trends in FDA's Oversight of Direct-to-Consumer Advertising United States Government Accountability Office GAO For Release on Delivery Expected at 10:00 a.m. EDT Thursday, May 8, 2008 Testimony Before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives PRESCRIPTION DRUGS Trends in FDA’s Oversight of Direct-to-Consumer Advertising Statement of Marcia Crosse Director, Health Care GAO-08-758T May 8, 2...
Date April 22, 2008	Report No. GAO-08-701T	Title Drug Safety: Preliminary Findings Suggest Recent FDA Initiatives Have Potential, but Do Not Fully Address Weaknesses in Its Foreign Drug Inspection Program United States Government Accountability Office GAO For Release on Delivery Expected at 11:00 a.m. EDT Tuesday, April 22, 2008 Testimony Before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives DRUG SAFETY Preliminary Findings Suggest Recent FDA Initiatives Have Potential, but Do Not Fully Address Weaknesses in Its Foreign Drug Inspection P...
Date April 4, 2008	Report No. GAO-08-327	Title DOD Pharmacy Program: Continued Efforts Needed to Reduce Growth in Spending at Retail Pharmacies United States Government Accountability Office GAO April 2008 Report to Congressional Committees DOD PHARMACY PROGRAM Continued Efforts Needed to Reduce Growth in Spending at Retail Pharmacies GAO-08-327 April 2008 DOD PHARMACY PROGRAM Highlights Highlights of GAO-08-327, a report to congressional committees Accountability Integrity Reliability Continued Efforts Needed to Reduce Growth in Spending...
Date Jan. 22, 2008	Report No. GAO-08-47	Title Medicare Part D: Plan Sponsors' Processing and CMS Monitoring of Drug Coverage Requests Could Be Improved United States Government Accountability Office GAO January 2008 Report to Congressional Requesters MEDICARE PART D Plan Sponsors’ Processing and CMS Monitoring of Drug Coverage Requests Could Be Improved GAO-08-47 January 2008 MEDICARE PART D Highlights Highlights of GAO-08-47, a report to congressional requesters Accountability Integrity Reliability Plan Sponsors’ Processing and CMS Monitorin...
Date June 26, 2007	Report No. GAO-07-1050T	Title End-Stage Renal Disease: Medicare Should Pay a Bundled Rate for All ESRD Items and Services United States Government Accountability Office GAO For Release on Delivery Expected at 10:00 a.m. EDT Tuesday, June 26, 2007 Testimony Before the Subcommittee on Health, Committee on Ways and Means, House of Representatives END-STAGE RENAL DISEASE Medicare Should Pay a Bundled Rate for All ESRD Items and Services Statement for the Record of A. Bruce Steinwald Director, Health Care GAO-07-1050T Mr....
Date June 21, 2007	Report No. GAO-07-1022T	Title Medicare Part D: CMS's Process and Policy for Enrolling New Dual-Eligible Beneficiaries United States Government Accountability Office GAO For Release on Delivery Expected at 2:00 p.m. EDT Thursday, June 21, 2007 Testimony Before the Subcommittee on Health, Committee on Ways and Means, House of Representatives MEDICARE PART D CMS’s Process and Policy for Enrolling New DualEligible Beneficiaries Statement of Kathleen M. King Director, Health Care GAO-07-1022T June 21, 2007 MEDICARE ...
Date May 31, 2007	Report No. GAO-07-555	Title Medicare Part D Low-Income Subsidy: Additional Efforts Would Help Social Security Improve Outreach and Measure Program Effects United States Government Accountability Office GAO May 2007 Report to the Committee on Finance, U.S. Senate MEDICARE PART D LOW-INCOME SUBSIDY Additional Efforts Would Help Social Security Improve Outreach and Measure Program Effects GAO-07-555 May 2007 Highlights Highlights of GAO-07-555, a report to the Committee on Finance, U.S. Senate Accountability Integrity Reliability MEDICARE PART D LOW-IN...
Date May 31, 2007	Report No. GAO-07-572	Title Retiree Health Benefits: Majority of Sponsors Continued to Offer Prescription Drug Coverage and Chose the Retiree Drug Subsidy United States Government Accountability Office GAO May 2007 Report to Congressional Committees RETIREE HEALTH BENEFITS Majority of Sponsors Continued to Offer Prescription Drug Coverage and Chose the Retiree Drug Subsidy GAO-07-572 May 2007 RETIREE HEALTH BENEFITS Highlights Highlights of GAO-07-572, a report to congressional committees Accountability Integrity Reliability Majority of Sponsors Con...
Date May 9, 2007	Report No. GAO-07-856T	Title Drug Safety: Further Actions Needed to Improve FDA's Postmarket Decision-making Process United States Government Accountability Office GAO For Release on Delivery Expected at 10:00 a.m. EDT May 9, 2007 Testimony Before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives DRUG SAFETY Further Actions Needed to Improve FDA’s Postmarket Decision-making Process Statement of Marcia Crosse Director, Health Care GAO-07-856T May 9, 2007 DRUG SAFETY Highligh...
Date May 8, 2007	Report No. GAO-07-824T	Title Medicare Part D: Enrolling New Dual-Eligible Beneficiaries in Prescription Drug Plans United States Government Accountability Office GAO For Release on Delivery Expected at 10:00 a.m. EDT Tuesday, May 8, 2007 Testimony Before the Committee on Finance, U.S. Senate MEDICARE PART D Enrolling New Dual-Eligible Beneficiaries in Prescription Drug Plans Statement of Kathleen M. King Director, Health Care GAO-07-824T May 8, 2007 MEDICARE PART D Highlights Highlights of GAO-07-824T, a testi...
Date May 8, 2007	Report No. GAO-07-858T	Title Medicare Part D Low-Income Subsidy: Progress Made in Approving Applications, but Ability to Identify Remaining Individuals Is Limited United States Government Accountability Office GAO For Release on Delivery Expected at 10:00 a.m. EDT Tuesday, May 8, 2007 Testimony before the Senate Committee on Finance MEDICARE PART D LOW-INCOME SUBSIDY Progress Made in Approving Applications, but Ability to Identify Remaining Individuals Is Limited Statement of Barbara Bovbjerg, Director Education, Workforce, and Income Security Issues GAO-07...
Date May 4, 2007	Report No. GAO-07-272	Title Medicare Part D: Challenges in Enrolling New Dual-Eligible Beneficiaries United States Government Accountability Office GAO May 2007 Report to Congressional Requesters MEDICARE PART D Challenges in Enrolling New Dual-Eligible Beneficiaries GAO-07-272 May 2007 MEDICARE PART D Highlights Highlights of GAO-07-272, a report to congressional requesters Accountability Integrity Reliability Challenges in Enrolling New Dual-Eligible Beneficiaries Why GAO Did This Study Since J...
Date March 22, 2007	Report No. GAO-07-599T	Title Drug Safety: FDA Needs to Further Address Shortcomings in Its Postmarket Decision-making Process United States Government Accountability Office GAO For Release on Delivery Expected at 9:30 a.m. EDT March 22, 2007 Testimony Before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives DRUG SAFETY FDA Needs to Further Address Shortcomings in Its Postmarket Decisionmaking Process Statement of Marcia Crosse Director, Health Care GAO-07-599T Ma...
Date Feb. 9, 2007	Report No. GAO-07-481T	Title Prescription Drugs: Oversight of Drug Pricing in Federal Programs United States Government Accountability Office GAO For Release on Delivery Expected at 10:00 a.m. EST Friday, February 9, 2007 Testimony Before the Committee on Oversight and Government Reform, House of Representatives PRESCRIPTION DRUGS Oversight of Drug Pricing in Federal Programs Statement of John E. Dicken Director, Health Care GAO-07-481T February 9, 2007 PRESCRIPTION DRUGS Highlights Highlig...
Date Jan. 11, 2007	Report No. GAO-07-358T	Title Prescription Drugs: An Overview of Approaches to Negotiate Drug Prices Used by Other Countries and U.S. Private Payers and Federal Programs United States Government Accountability Office GAO For Release on Delivery Expected at 10:00 a.m. EST Thursday, January 11, 2007 Testimony Before the Committee on Finance, U.S. Senate PRESCRIPTION DRUGS An Overview of Approaches to Negotiate Drug Prices Used by Other Countries and U.S. Private Payers and Federal Programs Statement of John E. Dicken Director, Health Care GAO-07-358T January 11, 200...
Date Dec. 22, 2006	Report No. GAO-07-239R	Title Medicaid Outpatient Drugs: Estimated 2007 Federal Upper Limits for Reimbursement Compared with Retail Pharmacy Acquisition Costs United States Government Accountability Office Washington, DC 20548 December 22, 2006 The Honorable Joe Barton Chairman Committee on Energy and Commerce House of Representatives Subject: Medicaid Outpatient Prescription Drugs: Estimated 2007 Federal Upper Limits for Reimbursement Compared with Retail Pharmacy Acquisition Costs Dear Mr. Chairman: Spending on outpatient prescription drugs in Medicai...
Date Dec. 6, 2006	Report No. GAO-07-266T	Title End-Stage Renal Disease: Medicare Payments for All ESRD Services, Including Injectable Drugs, Should Be Bundled United States Government Accountability Office GAO For Release on Delivery Expected at 10:30 a.m. EST Wednesday, December 6, 2006 Testimony Before the Committee on Ways and Means, House of Representatives END-STAGE RENAL DISEASE Medicare Payments for All ESRD Services, Including Injectable Drugs, Should Be Bundled Statement of David M. Walker Comptroller General of the United States GAO-07-266T Mr...
Date Nov. 17, 2006	Report No. GAO-07-49	Title New Drug Development: Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts United States Government Accountability Office GAO November 2006 Report to Congressional Requesters NEW DRUG DEVELOPMENT Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts GAO-07-49 November 2006 NEW DRUG DEVELOPMENT Highlights Highlights of GAO-07-49, a report to congressional requesters Accountability Integrity Reliability Science, Busines...
Date Nov. 16, 2006	Report No. GAO-07-54	Title Prescription Drugs: Improvements Needed in FDA's Oversight of Direct-to-Consumer Advertising United States Government Accountability Office GAO November 2006 Report to Congressional Requesters PRESCRIPTION DRUGS Improvements Needed in FDA’s Oversight of Direct-to-Consumer Advertising GAO-07-54 November 2006 PRESCRIPTION DRUGS Highlights Highlights of GAO-07-54, a report to congressional requesters Accountability Integrity Reliability Improvements Needed in FDA’s Oversight of Direct-to...

130 results

« ← Previous 1 2 3 Next → »

Weekly Updates

Caught Our Eye Rss

Social Media

DevBlog Rss

In the News

GAO Reports by subject "Prescription drugs"

Search Results: